Pasithea Therapeutics Corp. (KTTA)
NASDAQ: KTTA · Real-Time Price · USD
0.5050
-0.0344 (-6.38%)
At close: Aug 24, 2026, 4:00 PM EDT
0.5050
0.00 (0.00%)
After-hours: Aug 24, 2026, 4:10 PM EDT
Pasithea Therapeutics Employees
Pasithea Therapeutics had 5 employees as of December 31, 2025. The number of employees increased by 1 or 25.00% compared to the previous year.
Employees
5
Change (1Y)
1
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$4,258,324
Market Cap
16.87M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 5 | 1 | 25.00% | 5 | 0 |
| Dec 31, 2024 | 4 | -4 | -50.00% | 4 | 0 |
| Dec 31, 2023 | 8 | -7 | -46.67% | 8 | 0 |
| Dec 31, 2022 | 15 | 10 | 200.00% | 15 | 0 |
| Dec 31, 2021 | 5 | 2 | 66.67% | 3 | 2 |
| Jun 30, 2021 | 3 | - | - | 1 | 2 |
| Mar 31, 2021 | 3 | - | - | 1 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| Palatin Technologies | 29 |
| CalciMedica | 16 |
| Lipocine | 14 |
| NewcelX | 12 |
| Tvardi Therapeutics | 12 |
| Psyence Biomedical | 12 |
| Lexaria Bioscience | 7 |
KTTA News
- 10 days ago - Pasithea Therapeutics Quarterly report: Q2 2026 - Filings
- 17 days ago - Pasithea Therapeutics Proxy statement: Proxy filing - Filings
- 26 days ago - Pasithea Therapeutics Proxy statement: Proxy filing - Filings
- 26 days ago - Pasithea Therapeutics Slides: Corporate presentation - Filings
- 4 weeks ago - Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026 - GlobeNewsWire
- 6 weeks ago - Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit - GlobeNewsWire
- 7 weeks ago - Pasithea Therapeutics announces updated data from PAS-004 trial - TheFly
- 7 weeks ago - Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion - GlobeNewsWire